Stockscreener 앱 받기
6.29
4.31%
0.26
시장 영업 전:
6.01
-0.28
-4.45%
Eupraxia Pharmaceuticals Inc 주식(EPRX)의 최신 뉴스
Eupraxia Pharmaceuticals, Inc. Financial Disclosures & Filings - TradingView
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesDebt Analysis Report - newsline.com
Osteoarthritis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2036 – DelveInsight | Merck KGaA, Peptinov, LG Chem, Akan Bioscience, BioTissue,Inc., Eupraxia Pharma - Barchart
Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders - The Globe and Mail
Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K - TipRanks
Eupraxia (EPRX) details 2026 virtual AGM, board nominees and pay plan - Stock Titan
Eupraxia Pharmaceuticals (EPRX) confirms mailing of proxy materials to holders - Stock Titan
EPRX Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineEarnings Revision Downgrade - The Legal Advocate
Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference - TipRanks
Eupraxia Pharmaceuticals (EPRX) to present at Jefferies Global Healthcare Conference - Stock Titan
(EPRX.WT.A) Equity Market Report - Stock Traders Daily
Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - NorthBayNipissing.com
Biotech Eupraxia heads to New York for Jefferies health conference June 3 - Stock Titan
Eupraxia Pharmaceuticals (EPRX) Rises 2.3% as Stock Approaches Key Resistance LevelDay Trade Opportunities - newsline.com
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Earnings: Clinical Progress Overshadows Slight EPS MissLong-Term Guidance - Newser
Stifel Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Miss: What Went WrongCommunity Exit Signals - Newser
Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target - Moomoo
This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Certain Non-Voting Class B Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Common Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating - Investing.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating - Moomoo
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Manchester entities, Besser & Frank disclose EPRX holdings (EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing - TipRanks
Eupraxia Pharmaceuticals: Well-capitalized Into 2H28 >EPRX.T - Moomoo
Eupraxia Pharmaceuticals reports first quarter 2026 financial results - marketscreener.com
Eupraxia Pharmaceuticals Q1 Loss Narrows - Moomoo
Eupraxia (NASDAQ: EPRX) funds EP-104GI trial despite higher quarterly loss - Stock Titan
Eupraxia Pharmaceuticals Says "Well-capitalized into Second Half 2028, Beyond Key Catalysts" With Over US$140M Cash - marketscreener.com
Eupraxia Pharmaceuticals Cites "Robust Response" In Highest Dose Cohort After 36 Weeks Following a Single Treatment of EP-104GI - marketscreener.com
Eupraxia Pharmaceuticals Incurred a Q1 Net Loss of US$12.7M - marketscreener.com
EPRX: Eupraxia Pharmaceuticals Inc.Interactive Chart - Zacks Investment Research
Aisling Capital Management LP's Eupraxia Pharmaceuticals Inc(EPRX) Holding History - GuruFocus
TradingKey - TradingKey
Number of shareholders of Eupraxia Pharmaceuticals, Inc. – FWB:X43 - TradingView
Eupraxia wins new (US) $15.50 target at Leede Financial - Cantech Letter
Eupraxia reports EoE trial data on inflammation and fibrosis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Inc. - Menafn.com
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia reports EoE trial data on inflammation and fibrosis - Investing.com UK
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - The Manila Times
In Eupraxia’s top-dose EoE cohort, tissue scores improved >90% - Stock Titan
Eupraxia (EPRX) shows >90% EoE tissue score gains at top RESOLVE dose - Stock Titan
Eupraxia reports endoscopy score data from EoE trial By Investing.com - Investing.com Australia
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
2.60%
0.94%
자본화:
|
볼륨(24시간):